Edgewise Therapeutics, Inc. Stock Price, News & Analysis

Edgewise Therapeutics (Nasdaq: EWTX) announced on November 12, 2025 that it granted inducement equity awards in connection with the hire of Michael Nofi as Chief Financial Officer, effective the same day. On November 10, 2025 the company granted a stock option to purchase 262,500 shares and an inducement restricted stock unit award covering 43,750 shares under the 2024 Inducement Equity Incentive Plan.

The option’s exercise price is $18.17 per share (equal to the grant‑date closing price). Vesting: options—25% after one year then 1/48th monthly; RSUs—1/4 each year for four years. Awards were granted as inducements per Nasdaq Listing Rule 5635(c)(4).

Edgewise Therapeutics (Nasdaq: EWTX) announced the appointment of Michael Nofi as Chief Financial Officer, effective November 10, 2025, and the retirement of current CFO R. Michael Carruthers. Mr. Nofi joins from SpringWorks Therapeutics, where he served as Chief Accounting Officer for six years, and brings over 30 years of finance and accounting leadership in life sciences. The company said Carruthers guided Edgewise through its successful IPO and subsequent financings over the past five years and will support the transition into retirement. Edgewise highlighted Nofi's experience scaling finance operations and preparing organizations for commercialization as relevant as the company advances late-stage clinical programs.

Edgewise Therapeutics (Nasdaq: EWTX) announced management will participate in three investor conference fireside chats in November–December 2025.

Schedule: Guggenheim Healthcare Innovation on Nov 11, 2025 at 8:30 AM ET; Piper Sandler Healthcare on Dec 2, 2025 at 2:00 PM ET; Evercore Healthcare on Dec 3, 2025 at 3:25 PM ET. Webcasts will be available on the company Events & Presentations page and accessible for replay for a limited time. Users are advised to connect several minutes early to ensure timely access to each live webcast.

Edgewise Therapeutics (Nasdaq: EWTX) reported Q3 2025 results and program updates on Nov 6, 2025. Cash and marketable securities were approximately $563.3M as of Sept 30, 2025. The company continues clinical progress across muscular dystrophy and cardiac programs: GRAND CANYON (Becker) enrolled 175 adults with topline expected in Q4 2026; MESA open-label extension is ~99% enrolled. LYNX and FOX Duchenne studies identified a 10 mg dose and plan Phase 3 engagement in 2026. CIRRUS-HCM program update due Q4 2025; EDG-15400 Phase 1 topline expected H1 2026. Q3 operating highlights: R&D expense $37.5M, G&A $9.4M, net loss $40.7M ($0.39 per share).

Edgewise Therapeutics (Nasdaq: EWTX) announced inducement equity awards on November 3, 2025. On October 31, 2025, the company granted inducement stock options to purchase 170,750 shares to seven new non-executive employees under the 2024 Inducement Equity Incentive Plan.

Each option has an exercise price of $18.28 (equal to the closing price on the grant date). Vesting is 25% after one year, then 1/48th monthly thereafter, subject to continued service. Awards were granted as inducements under Nasdaq Listing Rule 5635(c)(4).

Edgewise Therapeutics (Nasdaq: EWTX) announced on October 2, 2025 that it granted inducement awards on September 30, 2025 to nine new non-executive employees under its 2024 Inducement Equity Incentive Plan.

The grants consist of 247,000 stock options with an exercise price of $16.22 (equal to the closing price on the grant date) and 15,000 RSUs. Options vest 25% after one year then monthly over 3 years; RSUs vest 1/4 annually over four years. Awards were granted as inducements per Nasdaq Rule 5635(c)(4).

Edgewise Therapeutics (NASDAQ:EWTX) will present key findings on sevasemten, their oral treatment for Becker and Duchenne muscular dystrophies, at the 30th International Annual Congress of the World Muscle Society in Vienna, Austria (October 7-11, 2025).

The company will host a symposium on October 8, 2025, featuring presentations from key opinion leaders discussing natural history insights and clinical progress. Three scientific posters will be presented on October 10, highlighting results from the CANYON trial in Becker muscular dystrophy, trajectory data compared to natural history, and LYNX Phase 2 trial results in DMD that will inform Phase 3 design.

Edgewise Therapeutics (Nasdaq: EWTX), a biopharmaceutical company focused on muscle diseases, has granted inducement stock options to 2 new non-executive employees. The options allow the purchase of 16,500 shares at an exercise price of $14.35 per share, matching the closing price on the grant date of August 29, 2025.

The options, granted under the company's 2024 Inducement Equity Incentive Plan, will vest over four years, with 25% vesting after one year and the remaining vesting monthly at a rate of 1/48th, contingent on continued employment. These grants comply with Nasdaq Listing Rule 5635(c)(4) as employment inducements.

Edgewise Therapeutics (NASDAQ:EWTX) reported its Q2 2025 financial results and clinical progress. The company announced positive top-line data from multiple trials of sevasemten in muscular dystrophy patients. Key highlights include 99% enrollment in the MESA open-label extension trial for Becker muscular dystrophy, showing sustained disease stabilization over 18 months.

The company completed enrollment of 175 adults in the GRAND CANYON pivotal trial, with topline data expected in Q4 2026. For Duchenne muscular dystrophy, encouraging results were reported from the LYNX and FOX Phase 2 trials. Additionally, Edgewise is advancing its CIRRUS-HCM Phase 2 trial of EDG-7500 for Hypertrophic Cardiomyopathy.

Financially, Edgewise maintains a strong position with $594.0 million in cash and equivalents. Q2 2025 R&D expenses were $33.6 million, down from $36.8 million in Q1, with a net loss of $36.1 million ($0.34 per share).